**Guideline Page and Request**

**Endometrial Carcinoma ENDO-B**

**Internal request:**
Add carboplatin/docetaxel as a systemic therapy option for the treatment of recurrent, metastatic or high-risk disease in endometrial carcinoma

**Panel Discussion**

Based upon discussion and the noted references, the panel consensus was to add carboplatin/docetaxel as a systemic therapy option for the treatment of recurrent, metastatic or high-risk disease in endometrial carcinoma. A corresponding footnote was added that states, “Docetaxel may be considered for patients in whom paclitaxel is contraindicated.”

**References**


**Vote**

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>